July 31, 2015
The National Cancer Institute’s Small Business Innovation Research (SBIR) Development Center recently announced new contract funding opportunities in a range of novel technology areas including molecularly targeted radiation therapy (TRT) for cancer treatment.
The short-term goal of the NIH/NCI 346 project is to perform feasibility studies for development and use of possible radioimmunotherapeutics for the treatment of cancer. The long-term goal of the project is to enable a small business to bring a fully developed TRT compound to the clinic and eventually to the market.
This contract solicitation seeks to stimulate research, development, and commercialization of innovative TRT techniques that could potentially shorten treatment cycles and reduce toxicity to normal tissues.
Proposals addressing the following technology areas are encouraged: new treatment strategies; design, synthesis and evaluation of innovative ligands and radiotracers for TRT; novel radioisotope generators and radioisotope production techniques; dosimetry techniques; and new conjugation chemistries that can link the radioisotopes to targeting agents other than antibodies (e.g. existing small molecule chemotherapeutic drugs) are also encouraged.